COMPARATIVE ANALYSIS OF INFLUENCE OF DIFFERENT GROUPS ON DRUGS HYPOGLYCEMIC CARBOHYDRATE AND LIPID METABOLISM IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.24144/2077-6594.3.2020.209897Keywords:
type 2 diabetes, hypoglycemic drugs, carbohydrate metabolism, lipid metabolismAbstract
Purpose. To compare the effect of different treatment regimens in patients with type 2 diabetes mellitus (DM) on carbohydrate and lipid metabolism.
Materials and methods. On the basis of the therapeutic department of the municipal non-profit enterprise "Uzhhorod district clinical hospital of Uzhhorod district council of Zakarpattia region" 87 patients with a diagnosis of type 2 diabetes were examined in the period from April 2019 to February 2020. All subsequent data were statistically processed.
Results. During treatment and 6 months after discharge, patients in all groups showed an improvement in carbohydrate metabolism, but statistically significant results were found in patients treated with metformin , metformin in combination with glimepiride and metformin in combination with empagliflozin – (p<0,05). In contrast, statistically significant changes in lipid metabolism before and after treatment in patients of all experimental groups were not observed (p<0.05). And only in patients receiving metformin therapy, as well as metformin in combination with empagliflozin 6 months after discharge was reached the target level of HbA1c.
Conclusions. The use of oral drugs, including metformin and combinations with it, including empagliflozin, was associated with a more pronounced and gradual decrease in glucose and HbA1c in patients with type 2 diabetes compared with injectable insulin.
References
Всесвітній день боротьби з діабетом: що треба знати про хворобу. Міністерство охорони здоров’я від 14 листопада 2017 року. Режим доступу – https://moz.gov.ua/article/health/vsesvitnij-den-borotbi-z-diabetom-scho-treba-znati-pro-hvorobu.
Наказ Міністерства охорони здоров’я від 21 грудня 2012 року № 1118, Уніфікований клінічний протокол первинної та вторинної (спеціалізованої) медичної допомоги ЦД 2-го типу. Режим доступу – https://dec.gov.ua/wp-content/uploads/images/dodatki/2012_1118/2012_1118YKPMD.pdf.
Цитовський М. Н. Статистичний, клінічний та морфологічний аспекти впливу цукрового діабету на стан ССС / М. Н. Цитовськкий // Науковий вісник Ужгородського університету, серія «Медицина». – 2017. – Випуск 1 (55). – С. 168–177.
American Diabetes Association, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes // Diabetes care. – 2019. – 42.Supplement 1: S90-S102.
Cefalu W.T. American Diabetes Association Standards of Medical Care in Diabetes / G. Bakris, L. Blonde, J.M. Boulton // Diabetes Care – 2017 – № 40 – Р. 6–10.
George A.B. Handbook of obesity: epidemiology, etiology, and physiopathology / A. B. George, C. Bouchard // CRC Press Taylor & Francis Group – 2014 – № 1 – Р. 539–549.
Fiaccadori E. Targeting the Gut for Early Diagnosis, Prevention, and Cure of Diabetic Kidney Disease: Is the Phenyl Sulfate Story Another Step Forward? / E. Fiaccadori, C. Cosola, A. Sabatino // American Journal of Kidney Diseases – 2020. – Vol. 75.1. – P. 144-147.
Saydah S.H. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes / S.H. Saydah, J. Fradkin, C.C. Cowie // JAMA – 2014 – № 42 – Р. 291–335.
Tan Y. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence / Y. Tan, Z. Zhang, C. Zheng et all // Nature Reviews Cardiology. – 2020. – P. 1-23.
